CheckMate914
Por um escritor misterioso
Descrição
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
Adjuvant Nivolumab/Ipilimumab Fails to Meet DFS End Point in Localized RCC
SIU 2019: Adjuvant Therapy for High-risk Renal Cell Carcinoma: Current Status
Et de 3 ! CheckMate 914 : encore un essai négatif en adjuvant pour le rein
Adjuvant Immunotherapy in Resected Renal Cell Carcinoma: Déjà vu or Progress?
Enrique Grande on LinkedIn: #immunotherapy
Fine-Tuning the Wave of Innovation in RCC
Frontiers Adjuvant therapy for renal cell carcinoma, finally a new standard?
From neoadjuvant to second-line therapeutic options for RCC patients
Checkpoint inhibitor immunotherapy in kidney cancer
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma - European Urology
Adjuvant Nivolumab/Ipilimumab vs Placebo in Localized Renal Cell Carcinoma - The ASCO Post
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - ScienceDirect
de
por adulto (o preço varia de acordo com o tamanho do grupo)
